Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
October 10 2008 - 2:00PM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Oct. 10 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the
results of its Extraordinary General Meetings ("EGMs") held earlier
today. The outcome of the EGMs was as follows: all of the
resolutions passed and Jennifer L. Good and Kenneth J. Zuerblis
were appointed as External Directors of the Company until October
10, 2011. Following the EGMs, XTL's Audit Committee consists of Mr.
Zuerblis, Ms. Good and Dr. William Kennedy. With the election of
the External Directors by the shareholders and their automatic
inclusion in the Audit Committee, XTL has notified NASDAQ that it
currently has a valid Audit Committee under the Israeli Companies
Act and NASDAQ Marketplace Rule 4350(d)(2). ABOUT XTL
BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is
engaged in the development of therapeutics for the treatment of
diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a
triple reuptake inhibitor of serotonin, norepinephrine and
dopamine, which is currently in a Phase 2b study for the treatment
of diabetic neuropathic pain. XTL has out-licensed its novel
pre-clinical HCV small molecule inhibitor program. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2024 to Oct 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2023 to Oct 2024